Montreal Health Innovations Coordinating Center (MHICC), a fast-growing contract research organization, believes LifeSphere’s innovative use of automation and Generative AI is aligned with its pharmacovigilance plans.

Boston, Massachusetts, USA – July 16, 2024 – ArisGlobal, a technology company at the forefront of life sciences and creator of LifeSphere®, today announced that Canadian contract research organization (CRO), Montreal Health Innovations Coordinating Center (MHICC) has selected LifeSphere® MultiVigilance and Reporting & Analytics to advance its solutions.

MHICC makes this decision as part of plans to expand into safety services for its biopharma clients. This new focus will complement the service provider’s existing pre-market clinical activities, provided to multinational pharma and biotech organizations.

Via ArisGlobal’s CRO partnership model, MHICC will integrate LifeSphere MultiVigilance, an advanced end-to-end automation-based safety platform, into its planned pharmacovigilance activities, enabling the company to bring new safety services to market.

MHICC leveraged ArisGlobal’s deep domain expertise to determine MultiVigilance and Reporting & Analytics as the best solutions for its clients. Both MultiVigilance and Reporting & Analytics harness the latest technologies including next-generation AI to ensure maximum efficiency and differentiation in the proposition offered to MHICC’s clients.

Comenting on MHICC’s decision to harness LifeSphere to deliver its new services, Executive Director Sophie Tanguay, said: “ArisGlobal’s innovative application of advanced automation and the company’s willingness to tailor the perfect solution for our requirements, made LifeSphere the right choice for this strategic expansion of our services. Instead of feeling we had to adopt and use features we wouldn’t need as a CRO with specific needs, ArisGlobal has worked with us very closely to tailor the ideal combination of capabilities, which we can access via the Cloud. That flexibility, along with the richness of the platform, made LifeSphere the clear choice.”

MHICC came into being when professionals from varied disciplines joined forces on a cardiology clinical research project funded by the Canadian Institute of Health Research. Up to now, the CRO has both supported smaller academic studies and performed comprehensive point-to-point studies for multinational pharmaceuticals. Steady growth has allowed MHICC to branch out of its original cardiology therapeutic area and into fields such as oncology, neurology, gastroenterology and endocrinology, while strategic partnerships have opened the global market to the ambitious CRO.